Title: Bepotastine
CAS Registry Number: 190786-43-7
CAS Name: 4-[(S)-(4-Chlorophenyl)-2-pyridinylmethoxy]-1-piperidinebutanoic acid
Additional Names: betotastine
Molecular Formula: C21H25ClN2O3
Molecular Weight: 388.89
Percent Composition: C 64.86%, H 6.48%, Cl 9.12%, N 7.20%, O 12.34%
Literature References: Histamine H1-receptor antagonist. Prepn (stereochem. unspec.): A. Koda et al., EP 335586; eidem, US 4929618 (1989, 1990 both to Ube). Prepn of optically active salts: J. Kita et al., EP 949260 (1999 to Ube; Tanabe Seiyaku). Pharmacology: M. Kato et al., Arzneim.-Forsch. 47, 1116 (1997). Suppression of IL-5 production: O. Kaminuma et al., Biol. Pharm. Bull. 21, 411 (1998). Antiallergic activity in animal models: M. Ueno et al., Pharmacology 57, 206 (1998).
Derivative Type: Benzenesulfonate salt
CAS Registry Number: 190786-44-8
Additional Names: Bepotastine besilate
Manufacturers' Codes: TAU-284
Trademarks: Talion (Tanabe)
Molecular Formula: C21H25ClN2O3.C6H6O3S
Molecular Weight: 547.06
Percent Composition: C 59.28%, H 5.71%, Cl 6.48%, N 5.12%, O 17.55%, S 5.86%
Properties: Pale grey prisms from acetonitrile, mp 161-163°. [a]D20 +6.0° (c = 5 in methanol).
Melting point: mp 161-163°
Optical Rotation: [a]D20 +6.0° (c = 5 in methanol)
Therap-Cat: Antihistaminic.
Keywords: Antihistaminic.
Bepridil Beractant Beraprost Berbamine Berberine

Systematic (IUPAC) name
4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
Clinical data
AHFS/ International Drug Names
MedlinePlus a610012
Pregnancy cat. C (US)
Legal status Prescription only
Routes Oral, topical (eye drops)
Pharmacokinetic data
Bioavailability High (oral)
Minimal (topical)
Protein binding ~55%
Excretion Renal (75–90%)
CAS number 125602-71-3 N
ATC code None
PubChem CID 2350
DrugBank DB04890
ChemSpider 2260 YesY
KEGG D09705 YesY
Chemical data
Formula C21H25ClN2O3 
Mol. mass 388.88 g/mol
 N (what is this?)  (verify)

Bepotastine (Talion) is an antihistamine.[1] It was approved in Japan for use in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name TALION. TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. Senju, in turn, has granted the United States rights for the ophthalmic preparation to ISTA Pharmaceuticals, Inc., a specialty pharmaceutical company located in Irvine, CA.